Literature DB >> 22366251

Copy number aberrations in combined hepatocellular carcinoma and cholangiocarcinoma.

Huey-Ling You1, Shao-Wen Weng, Shau-Hsuan Li, Yu-Ching Wei, Jim Jinn-Chyuan Sheu, Chih-Mei Chen, Wan-Ting Huang.   

Abstract

Combined hepatocellular carcinoma and cholangiocarcinoma (CHC) is a rare liver cancer which shares unequivocal features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). A greater awareness of genetic relationship between HCC and CC components is limited. To help characterize this rare liver neoplasm, we described clinicopathologic features and evaluated copy number (CN) changes in this study. A total of 13 cases of CHC were collected. Four paired HCC and CC components from four cases were first subject to genome-wide analysis. Nine target genes were subsequently selected for further analysis using quantitative polymerase chain reaction. The paired HCC and CC components in each case had a concordant trend of CN gain or loss in these nine genes. However, the magnitude of concordant CN gain or loss was different. There were significant differences of CN copies between HCC and CC in each case. We demonstrate genetic divergence between HCC and CC components in CHC.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366251     DOI: 10.1016/j.yexmp.2012.01.009

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  4 in total

1.  Genome-wide single nucleotide polymorphism array analysis reveals recurrent genomic alterations associated with histopathologic features in intrahepatic cholangiocarcinoma.

Authors:  Wan-Ting Huang; Shao-Wen Weng; Yu-Ching Wei; Huey-Ling You; Jui-Tzu Wang; Hock-Liew Eng
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma.

Authors:  Olga Raevskaya; Henry Appelman; Nataliya Razumilava
Journal:  Curr Hepatol Rep       Date:  2020-10-31

3.  Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma.

Authors:  Ting-Ting Liu; Huey-Ling You; Shao-Wen Weng; Yu-Ching Wei; Hock-Liew Eng; Wan-Ting Huang
Journal:  PLoS One       Date:  2015-12-18       Impact factor: 3.240

Review 4.  Clinical features, histology, and histogenesis of combined hepatocellular-cholangiocarcinoma.

Authors:  Shweta Gera; Mark Ettel; Gabriel Acosta-Gonzalez; Ruliang Xu
Journal:  World J Hepatol       Date:  2017-02-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.